Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SZM-1209 is a potent and specific RIPK1 inhibitor with oral activity, displaying a dissociation constant (Kd) of 85 nM. It demonstrates substantial anti-necroptotic efficacy with an EC50 of 22.4 ± 8.1 nM and possesses therapeutic effects against systemic inflammatory response syndrome (SIRS) and acute lung injury (ALI) [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | 35 days | $ 193.00 | |
5 mg | 35 days | $ 765.00 |
Description | SZM-1209 is a potent and specific RIPK1 inhibitor with oral activity, displaying a dissociation constant (Kd) of 85 nM. It demonstrates substantial anti-necroptotic efficacy with an EC50 of 22.4 ± 8.1 nM and possesses therapeutic effects against systemic inflammatory response syndrome (SIRS) and acute lung injury (ALI) [1]. |
Targets&IC50 | RIPK1:85 nM (Kd), RIPK3:>10000 nM (Kd) |
In vitro | SZM-1209 blocks necroptotic cell death in a dose-dependent manner [1]. Specifically, SZM-1209 (0-1 μM, 6 h) inhibits the phosphorylation of the necroptosis signaling pathway involving RIPK1, RIPK3, and MLKL [1]. |
In vivo | SZM-1209 administered at doses ranging from 25 to 100 mg/kg through oral gavage (灌胃) significantly counteracts inflammation in a systemic inflammatory response syndrome (SIRS) model induced by mTNF-α, reversing mortality in mice [1]. Additionally, when injected intraperitoneally (腹腔注射) at the same dosage, SZM-1209 markedly alleviates acute lung injury (ALI) by reducing pulmonary edema and pathological damage [1]. |
Molecular Weight | 696.71 |
Formula | C31H29F5N4O5S2 |
CAS No. | 2919801-86-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SZM-1209 2919801-86-6 Apoptosis NF-Κb RIP kinase inhibitor inhibit